Rachel Riechelmann, Director of Clinical Oncology, Head of Neuroendocrine Tumors Reference Center at A.C.Camargo Cancer Center, shared a post by Common Sense Oncology on LinkedIn, adding:
“We invite you to be part of the Common Sense Oncology movement.
In this 1st webinar, we will discuss how to treat HER2+ breast based on outcomes that really matter to patients. Spread the word to your colleagues, residents, groups!”
Quoting Common Sense Oncology:
“Brazil Hub: Controversies in clinical oncology: treatment of locally advanced HER2-positive breast cancer
Friday 14/08/2026 | 4:00 p.m. (Brasilia; UTC-3:00)
Join us online for a discussion on neoadjuvant therapy for patients with HER2+ breast cancer based on the principles of Common Sense Oncology.
